Suppl table 2: Summary of parameters recorded from a cohort of 112 adults with HBV infection in Cape Town, South Africa, comparing features of those with HBV monoinfection (n=74) versus HIV/HBV coinfection (n=38). This is an extended version of tables 1 and 2 presented in the main text.

	Whole Cohort	HBV monoinfection	HIV/HBV coinfection	p-value <sup>a</sup>
Sex M:F (% male)	62:50 (%)	44:30 (%)	18:20 (%)	0.24
Median age in years at enrollment <sup>b</sup> (IQR)	44 (36-53)	46 (36-55)	41 (37-50)	0.28
Median body weight in kg <sup>c</sup> (IQR)	73 (60-85)	75 (60-87)	72 (59-80)	0.20
Proportion HBeAg positive <sup>d</sup> (%)	20/102 (19.6%)	8/67 (11.9%)	12/35 (34.3%)	0.009
Median ALT in males, iu/mle (IQR)	29 (21-43)	31 (22-45)	27 (21-39)	0.66
Median ALT in females, iu/mle (IQR)	18 (16-23)	18 (15-22)	18 (16-25)	0.39
Proportion with elevated ALT above ULN (%)	49/109 (45%)	33/72 (46%)	16/37 (43%)	0.84
Median AST, iu/mlf (IQR)	29 (22-44)	29 (22-46)	31 (21-43)	0.87
Proportion with elevated AST above ULN (%)	27/85 (32%)	16/50 (32%)	11/35	1.0
Median BR, mmol/L (IQR)	7 (5-13)	9 (5-15)	5 (4-9)	0.003
Proportion with elevated BR above ULN <sup>9</sup> (%)	14/95 (14.7%)	12/61 (19.7%)	2/34 (6.0%)	0.08
Median platelet count, x10 <sup>3</sup> / ul (IQR)	226 (158-292)	227 (153-291)	249 (166-307)	0.38
Proportion with thrombocytopaenia <sup>h</sup> (%)	10/97 (10.3%)	10/62 (16%)	0/35 (0%)	0.01
Proportion with CKD II or III <sup>i</sup> (%)	31/99 (31%)	21/63 (33%)	10/36 (28%)	0.66

Proportion with APRI score >2	8/79 (10%)	8/47 (17%)	0/32 (0%)	0.02
Proportion with FIB-4 score >3.25	12/78 (15%)	10/46 (22%)	2/32 (6%)	0.11
Proportion with documented clinical complications <sup>j</sup> (%)	18/106 (17%)	14/68 (21%)	4/38 (11%)	0.3
Proportion assessed by elastography (%)	38/112 (34%)	8/74 (11%)	30/38 (79%)	<0.0001
Median elastography score, kPa <sup>k</sup> (IQR)	5.7 (4.7-8.2)	6.9 (4.9-10.9)	5.6 (4.5-7.0)	0.28
Proportion with elastography score >6kPa (%)	16/38 (42%)	4/8 (50%)	12/30 (40%)	0.7
Proportion with elastography score >9kPa (%)	7/38 (18%)	3/8 (38%)	4/30 (13%)	0.14
Proportion on antiviral treatment <sup>1</sup> (%)	71/108 (66%)	34/70 (49%)	37/38 (97)	<0.0001
Median duration of therapy <sup>m</sup> , months (IQR)	31 (14-66)	29 (7-63)	37 (18-66)	0.1
Median HBV DNA viral load IU/ml <sup>n</sup> (range)	31 (0-1.7x10 <sup>8</sup> )	90 (0 - 1.7x10 <sup>8</sup> )	0 (0-1.0x10 <sup>8</sup> )	0.049
Proportion of HBV viraemia undetectable°	40/96 (42%)	20/61 (33%)	20/35 (57%)	0.03

IQR = inter-quartile range; ALT = alanine transferase; ULN = upper limit of normal. <sup>a</sup>p-value for categorical variables by Fisher's Exact Test, and for continuous variables by Mann Whitney test. <sup>b</sup>Age available for 111/112 individuals. <sup>c</sup>Body weight available for 108/112 individuals. <sup>d</sup>HBeAg status available for 102/112 individuals. <sup>e</sup>ALT available for 60/62 males and 49/50 females, with ULN defined as 19 iu/ml for females and 30 iu/ml for males. <sup>f</sup>AST available for 85/112 individuals, with ULN defined as 40 iu/ml. <sup>g</sup>BR available for 95/112 individuals; ULN defined as 17 mmol/L. <sup>h</sup>Platelet count available for 97/112 individuals; moderate/severe thrombocytopaenia defined as platelet count <75 x10<sup>3</sup> / ul [26]. <sup>i</sup>CKD (chronic kidney disease) stages II and III defined as eGFR <90 ml/min/1.73m<sup>2</sup>. <sup>j</sup>Clinical complications reviewed for 108/112 individuals, defined as a documented diagnosis of HCC and/or cirrhosis. <sup>k</sup>Elastography data available for 38/112 individuals. <sup>l</sup>Antiviral treatment data available for 108/112 individuals. <sup>m</sup>Duration of therapy defined for 29 HBV monoinfected and 27 HBV/HIV coinfected individuals. <sup>n</sup>HBV DNA viral load available for 61/74 HBV monoinfected and 35/38 HIV coinfected individuals. <sup>c</sup>Undetectable HBV DNA defined as viral load in serum below limit of detection of assay (typically HBV DNA <20 IU/ml).